Critical Contrast: GH Research (NASDAQ:GHRS) versus Tenax Therapeutics (NASDAQ:TENX)

GH Research (NASDAQ:GHRS) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Valuation and Earnings

This table compares GH Research and Tenax Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26 million	($0.92)	-24.04
Tenax Therapeutics	N/A	N/A	-$52.60 million	($1.40)	-8.66

GH Research is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

56.9% of GH Research shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 3.1% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares GH Research and Tenax Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Tenax Therapeutics	N/A	-56.32%	-53.12%

Analyst Recommendations

This is a summary of recent recommendations for GH Research and Tenax Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1	1	9	0	2.73
Tenax Therapeutics	1	0	4	1	2.83

GH Research presently has a consensus price target of $40.38, suggesting a potential upside of 82.53%. Tenax Therapeutics has a consensus price target of $29.67, suggesting a potential upside of 144.57%. Given Tenax Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than GH Research.

Volatility & Risk

GH Research has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Summary

GH Research beats Tenax Therapeutics on 8 of the 12 factors compared between the two stocks.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

About Tenax Therapeutics

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.